Postoperative nausea and vomiting (PONV) is a common and distressing problem for patients and increases the burden of care in post-anaesthesia care units (PACU). As such it has been a recent focus for quality improvement. Evidence-based guidelines have demonstrated the benefit of PONV risk stratification and prophylaxis, but may be underutilised in clinical practice. This prospective pre-/post-intervention study was conducted at an adult tertiary hospital in non-cardiac adult surgical patients at higher risk of PONV. The intervention included promotion of an evidence-based PONV guideline, and provision of individualised prescribing and patient outcome data to anaesthetists. Six hundred and twenty-eight patients with ≥2 risk factors for PONV following general anaesthesia for non-cardiac surgery were included (333 pre-intervention and 295 postintervention). Prior to the intervention, 9.0% (30/333) of moderate-and high-risk patients received antiemetic prophylaxis consistent with our guideline. Post-intervention, the rate of guideline adherence was 19.3% (57/295). In the high-risk PONV group, the time in PACU was significantly reduced post-intervention, 66 minutes versus 83 minutes (P=0.032). This institutionspecific PONV reduction strategy had a modest but significant effect on improving prophylaxis administration. However, our findings indicate that further efforts would be required to ensure fuller compliance with the current extensive evidence base for PONV management in higher-risk patients.
1
. The overall incidence of PONV after general anaesthesia is reported to be in the range of 10% to 30%, with higher-risk patients experiencing significantly higher rates of PONV. Recent consensus guidelines published by the Society for Ambulatory Anesthesia continue to draw attention to the benefit of PONV risk stratification and appropriate prophylaxis 2 . Despite the extensive evidence on prediction, prevention and treatment of PONV, it is thought the opportunity still exists for significant practice improvements 1 . Evidence-based guidelines are often poorly implemented by physicians generally 2 , and translation of the plethora of PONV research into clinical practice seems no exception 2 . Against this background, the Australian and New Zealand College of Anaesthetists recently endorsed PONV prophylaxis as a target for practice evaluation and auditing 2 . In Australia, PONV rates, risk factors, and impact on patient satisfaction have been investigated 2, 3 . A recent survey of anaesthetists found 71.1% of patients undergoing general anaesthesia received a prophylactic antiemetic, with practice largely consistent with current evidence 2 . Whilst survey research is a valuable tool it is susceptible to selection and recall bias.
To further elucidate current PONV prophylaxis practice we conducted a prospective observational study investigating antiemetic prophylaxis benchmarked against an evidencebased, locally developed PONV prophylaxis guideline, with a second observational phase after a targeted intervention to improve appropriate prophylaxis rates. Our hypothesis was that a multifaceted PONV reduction strategy would improve antiemetic prophylaxis rates at our institution. Although our guideline was developed for use at our institution, it is based on contemporary evidence and uses readily identifiable risk factors available prior to the conclusion of surgery.
Methods

Study design and participants
This study was conducted at St Vincent's Hospital Sydney, an urban adult tertiary referral hospital, as a pre-/ post-intervention cohort study assessing the effects of a multifaceted strategy to increase antiemetic prophylaxis for patients at moderate or high risk of early PONV. It was conducted in two two-month blocks (one before and one after an education intervention and individualised audit of practice). Patients were included if they underwent general anaesthesia and were transferred to the post-anaesthesia care unit (PACU) postoperatively. Patients were excluded if they proceeded to the intensive care unit postoperatively or if they received only regional anaesthesia or a sedation-based technique (e.g. endoscopy). The study was approved by the St Vincent's Hospital Health District Human Research Ethics Committee (LNR/15/SVH/143) with the need for individual informed consent waived.
Intervention
The educational intervention included dissemination of an evidence-based, locally developed PONV guideline to consultant and registrar anaesthetists at our institution, supported by individualised audit data. First, a preintervention audit of baseline performance was conducted, with prescribing and PONV outcome data for each prescriber benchmarked against departmental practice and the proposed guideline, stratified by PONV risk classification. Next, the proposed guideline and supporting evidence were introduced by an oral presentation to consultants and registrars, and disseminated via electronic mail and laminated posters throughout the operating suite. Anaesthetists were made aware that the guideline was not intended to constrain practice or a practitioner's clinical judgement. Prescribers also received via electronic mail an individualised and de-identified summary of the baseline audit data, showing their prescribing practices and PONV outcomes referenced against grouped departmental data and the proposed guideline, and stratified by PONV risk category. These data included PONV prophylaxis recommended by our guideline for each risk category, the actual strategies prescribed and the incidence of symptomatic PONV for their patients. Following this multifaceted intervention, a one-month washin period occurred prior to post-intervention data collection.
In the guideline, patients were assigned a risk score determined by the number of predefined risk factors, with one point assigned for each of: emetogenic surgery (cholecystectomy, gynaecological, or laparoscopic surgery), female gender, age <50 years, non-smoking status, and prior PONV or motion sickness (risk score range 0 to 5). Risk stratification was based on the clinical audit guide for PONV prophylaxis endorsed by the Australian and New Zealand College of Anaesthetists 6 . However, given the difficulty of predicting postoperative opioid use this risk factor was replaced with age <50 years, which has recently been shown to be a significant risk factor for PONV 2 . Our guideline recommended no or one antiemetic agent or strategy for low-risk (no or one risk factor); one or two strategies for moderate-risk (two factors), and three or more strategies for high-risk patients (three or more factors). For patients with no or one risk factor, current evidence regarding prophylaxis is equivocal, and 'no prophylaxis' may be considered appropriate. Total intravenous anaesthesia (TIVA) with propofol was considered a prophylactic strategy in this guideline. The recommendation for three or more antiemetic strategies for high-risk patients was based on previous studies suggesting that triple therapy prophylaxis (ondansetron, dexamethasone and droperidol) combined with TIVA resulted in the greatest reduction in PONV in high-risk patients 2 . The suggested strategies at our institution included any of: TIVA, dexamethasone (4 to 8 mg), either metoclopramide (10 mg) or droperidol (0.25 to 0.50 mg), ondansetron (4 to 8 mg) or cyclizine (25 to 50 mg) (all intravenous). Except for dexamethasone, which was administered after induction, all antiemetics were administered prior to emergence from anaesthesia. Each strategy or agent was considered equivalent; i.e. propofol TIVA plus ondansetron was counted as two prophylactic strategies.
Data collection
The primary outcome was the antiemetic guideline adherence, as measured before and after the intervention, amongst patients at moderate or high risk of PONV. Secondary outcomes included symptomatic PONV and duration of stay in PACU. The definition of symptomatic PONV was the administration of rescue antiemetic therapy during PACU admission. Rescue antiemetics were administered in response to retching, vomiting, or an affirmative patient response to the clinical question "Do you feel sick, nauseated or like you might vomit?" Rescue antiemetics were not given pre-emptively, i.e. as routine co-administration with an opioid. Nursing staff used a free-text field to report exceptions (e.g. patient refusal of rescue antiemetic, or lack of suitable therapy due to allergy or other clinical reason). During each two-month block (pre-and post-intervention), PACU registered nurses collected perioperative data, including demographic, PONV risk factors, anaesthetic data, use of opioids in PACU and the development of symptomatic PONV requiring rescue therapy. Data was collected using a data collection form which all PACU nurses were trained to administer. Intraoperative antiemetic prophylaxis was extracted from the anaesthetic charts, and PONV risk factors were recorded by review of pre-anaesthetic consultation notes and interview of the patient immediately prior to discharge from PACU. Duration of stay in PACU was determined from time of admission until readiness for discharge from PACU. Further data was not collected after discharge from PACU and assessments of later PONV were not undertaken.
Statistical analysis
The required sample size was derived following the initial pre-intervention baseline assessment. For reasons of convenience, the pre-intervention audit was performed over eight continuous weeks, and included 333 moderate-or highrisk cases, with a baseline adherence to guideline of 9%. In order to reliably identify a 100% increase in adherence (to 18%) with alpha=0.05 and 80% power, ≥222 post-intervention cases were required.
Parametric data are presented as means and compared using a Student's t-test, categorical data are presented as proportions, and analysed using a chi-squared test. Nonparametric data such as PACU stay was analysed with a log-rank test. All data was analysed using SPSS for Windows (version 22.0, IBM Corp., Armonk, NY, USA).
Results
During the pre-intervention phase, 333 of 581 included patients were at moderate or high risk; during the postintervention phase, 295 of 521 patients were at elevated risk. Demographic data are presented in Table 1 . Data for both pre-and post-intervention cohorts are shown benchmarked against the institutional guideline. The actual use of prophylactic strategies before and after the intervention are presented in Table 2 . Prior to the intervention, 9.0% (30/333) of moderate-and high-risk patients received antiemetic prophylaxis consistent with our guideline. Post-intervention, the rate of guideline adherence was 19.3% (57/295). There were modest increases in the use of prophylaxis in the moderate-and high-risk groups (by definition, low-risk patients could not be undertreated). For the purpose of benchmarking against the guideline, the use of propofol TIVA was considered an antiemetic strategy. For clarity, cases maintained with propofol have been shown separately to those receiving volatile anaesthetic. The actual use of antiemetic strategies is presented in Table 3 .
Patients receiving PONV prophylaxis in accordance with the intervention algorithm had significantly less early PONV, with this data being provided to anaesthetists as part of PONV, postoperative nausea and vomiting; TIVA, total intravenous anaesthesia. Time in PACU for all patients (arrival in PACU until ready for discharge, mean values) was not demonstrably shorter in the post-intervention phase, 68 minutes versus 75 minutes (P=0.054). In the high-risk PONV group, the time in PACU was significantly reduced post-intervention, 66 minutes versus 83 minutes (P=0.032). The occurrence of PONV had a significant impact on time in PACU. In the pre-intervention phase, patients with PONV were in PACU 101 minutes versus 71 minutes for those without PONV (P <0.001). In the post-intervention phase, patients with PONV were in PACU 95 minutes versus 65 minutes for those without PONV (P <0.001).
Discussion
The results of this study confirm that an intervention utilising promotion of a locally developed PONV prevention guideline, presentation of current evidence, and departmental in conjunction with individual performance feedback, increases antiemetic prophylaxis rates among patients at higher risk of PONV. However, these increases were relatively modest. Moderate-risk patients had a baseline early PONV rate of approximately 10%, which is less than otherwise predicted 2 . However, our study collected data on PONV rates during PACU admission and not after PACU discharge, possibly missing delayed episodes of PONV that may have significantly increased baseline rates.
Targeting higher-risk patients with the goal of significant reductions in PONV using multimodal prophylaxis is achievable and translates into improved patient satisfaction 11, 2 , and implementation of such strategies is considered worthwhile 3 . Of note, Hocking et al specifically addressed the issue of patient satisfaction and the influence of patient satisfaction feedback to anaesthetists 11 . In their study, PONV was identified as a major component of perception of quality in anaesthesia and feedback to anaesthetists led to a significant rise in the number of patients receiving an intraoperative 5HT3 antiemetic.
Despite the evidence base for a risk-stratified multimodal approach to PONV prophylaxis, implementation of such strategies is difficult 5 . Kappen et al recently reported that automated risk stratification alone did not influence PONV rates, and whilst it did result in administration of more agents to high-risk patients, there was still a reluctance to administer more than two antiemetics 2 . Our implementation phase included a multifaceted approach using strategies successfully employed elsewhere, and included providing current evidence to anaesthetists 2 , promotion of an institution-specific PONV prophylaxis algorithm 13 and feedback of departmental and individual baseline data 5 . This intervention did increase prophylaxis prescription, although nearly 40% of moderate-risk patients and over 80% of highrisk patients remained undertreated, a figure strikingly similar to the finding of Franck et al 3 .
The reasons why prophylaxis prescribing wasn't higher are unclear, but ongoing undertreatment is a recurrent theme. This study did not assess whether practitioners actually reviewed their audit data, or assess their interpretation of it. It is possible that providing audit data in a personal interview would ensure that practitioners are able to review and interpret the data. A personal interview would also reinforce the practice guideline, and may have a stronger impact. The disconnect between the evidence base and clinical implementation is notable, with the recently published consensus guidelines stating, "Perhaps, the biggest problem is that many anesthesia care providers fail to translate this knowledge into changes in practice" 2 . Whilst the intervention increased prophylaxis rates only modestly, there was a reduction in PACU stay in the highrisk group (17 minutes, P=0.032) supporting the face validity of the study. In all patients the occurrence of PONV was associated with a significant delay in PACU discharge (30 minutes, P <0.001). PONV reduction strategies may represent a significant target for not only improved patient outcomes but also operating suite efficiencies and patient flow, by reducing the duration of time patients spend in PACU and decreasing the risk of full PACUs delaying transfer of patients out of the operating theatre. Although there was a small increase in TIVA for high-risk patients following the intervention (from 5% to 13% of high-risk patients), TIVA use did not substantially change for the cohort overall. This is a well-established indication for a propofol anaesthetic and remains a significant opportunity for improvement, even among our high-risk patients, and should be targeted in future efforts. This study was conducted in a single institution limiting widespread application to other centres, and employed a prophylaxis algorithm developed for this hospital and adapted from the Society for Ambulatory Anesthesia and the Australian and New Zealand College of Anaesthetistsendorsed guidelines. However, the recommended antiemetics are available in many institutions, and the suggested doses are consistent with adult practice, thus permitting extrapolation to other non-cardiac adult populations. Furthermore, in the second phase of the study the audit itself may have altered prescribing practice. It is possible that after audit completion, prophylaxis patterns may regress towards the baseline. The ongoing effect of such an intervention is a possible direction for future research. We did not incorporate specific measures of PONV severity, duration or post-PACU nausea and vomiting, and the definition of PONV was based on the administration of a rescue antiemetic in PACU. Using rescue medication as a marker of PONV is a simple metric that has been used previously 13 . The use of a PONV impact scale may have enabled differentiation between mild and severe PONV and the relative effect on recovery 2 . However, this approach remains unvalidated and from the patient perspective nausea and vomiting is a significant concern 2 . Furthermore, in the absence of intraoperative and postoperative opioid exposure data, it is difficult to fully interpret PONV rates and compare between other institutions. This is a major limitation of this study.
Our findings indicate that PONV management remains a significant target for improved clinical practice. Despite the extensive evidence base, strategies such as risk stratification, reduction of baseline risk and rational antiemetic prescription 2 can be improved, especially in high-risk patients. A multifaceted implementation strategy resulted in modest improvements in PONV prophylaxis, but it is likely that repeated and further interventions would be required to create a sustained and more marked improvement. Given the evidence base is robust, the transfer of this into clinical practice is, as one recent commentator suggested, dependent on "...implementation" 2 .
